Please enter mandatory and valid details

OptraSCAN’s Patented Immuno Oncology Biomarker Analysis & PD-L1 Biomarker Analysis

For Immuno - Oncology – Programmed Death-Ligand 1 (PD-L1) Expression

Programmed Cell Death Ligand-1 expression or PD-L1 is an important cancer biomarker and has become a critical part of patient engagement for immunotherapy. The targeted blockade of PD-L1 may help to restore the antitumor response.

Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors has indicated that PD-L1 expression on both tumor and tumor-associated immune cells is associated with clinical outcome

Optrascan’s Solution For Immuno - Oncology

OptraSCAN’s PD-L1 automated image analysis (for research use) supports interpretation of PD-L1 IHC expression on both tumor and immune cells in solid tumors. It determines PD-L1 expression on tumor and immune cells showing partial or complete membrane staining on tumor cells along with membrane and/or cytoplasmic staining on immune cells in a single read. It is reliable and can be used to assess PD- L1 expression in a more objective manner.

General Considerations By The PD-L1 Assay

  • Fully automated algorithm evaluates and generates scores for both, regions of interest and whole slide analysis with minimal human intervention
  • Score generation based on the number of PD-L1 positive cells (tumor, lymphocytes and macrophages) in relation to total tumor cells allows capturing of tumor and immune cells in a single read
  • Fully integrated image acquisition and automated evaluation of tumor area for adequacy by confirming the presence of 100 viable tumor cells for interpretation using Computer aided region detection system based on Artificial Neural Network
  • Reporting module included with case management
OptraSCAN's AI & ML based scoring algorithms for PD-L1 expression

To know more about our AI & ML based scoring algorithms for PD-L1 expression.

Contact now

Analytical Components Assessed By OptraSCAN AI Tool

  • Tumor Cell staining (an estimate of the percentage of tumor cells exhibiting partial or complete membranous staining)
  • Immune Cell (IC) staining (an estimate of the percentage of ICs, including macrophages and lymphocytes, within the tumor, exhibiting staining)